Evidence map›Paper›PMID 40125233›Full record

ArticleCureus2025

Progressive Muscle Weakness and Dysphagia in Late-Onset Systemic Lupus Erythematosus: A Case Report.

Sho Fukuda, Kasumi Nishikawa, Ryuichi Ohta

Abstract readCase Reports
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Sho FukudaFmaily Medicine, Unnan City Hospital, Unnan, JPN.
Kasumi NishikawaFamily Medicine, Unnan City Hospital, Unnan, JPN.
Ryuichi OhtaCommunity Care, Unnan City Hospital, Unnan, JPN.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Late-onset systemic lupus erythematosus (SLE), defined as SLE developing after age 50, presents distinct clinical features influenced by immunosenescence. Compared to early-onset SLE, it often manifests with nonspecific symptoms such as myositis-like weakness, serositis, and subtle systemic features, complicating timely diagnosis. Given the complexity of comorbidities in elderly patients, distinguishing late-onset SLE from other conditions is critical for appropriate management. We report a case of a 76-year-old man who presented with progressive lower limb weakness and dysphagia. Initial investigations, including laboratory tests, autoantibody profiling, imaging, and nerve conduction studies, led to the diagnosis of late-onset SLE with neuromuscular involvement. The patient exhibited significant systemic symptoms, including muscle weakness, hematologic abnormalities, and pulmonary involvement. Prompt initiation of methylprednisolone pulse therapy followed by intravenous immunoglobulin (IVIG) and oral corticosteroids led to a marked improvement in muscle strength and swallowing function. Within 36 days, he regained independence in activities of daily living (ADL) and was transferred for rehabilitation. This case highlights the diagnostic challenges and therapeutic considerations in late-onset SLE. Myositis and dysphagia, though uncommon, can be prominent in elderly patients, necessitating a high index of suspicion. Early recognition and a multidisciplinary approach are essential for optimizing treatment and functional recovery.

Indexed as

corticosteroid therapydysphagiafamily medicinegeneral medicinelate-onset systemic lupus erythematosusmultidisciplinary managementmyositisneuromuscular involvementrural

Identifiers

PMID40125233
PMCPMC11928338

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.